$4.87
At close: Apr 21 EDT
$4.87
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
ORIC Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ORIC | Benzinga
ORIC Pharmaceuticals Inc has a consensus price target of $20.1 based on the ratings of 12 analysts. The high is $27 issued by Baird on August 16, 2023. The low is $14 issued by Citigroup on May 7, 2024. The 3 most-recent analyst ratings were released by JP Morgan, HC Wainwright & Co., and HC Wainwright & Co. on February 26, 2025, February 26, 2025, and February 24, 2025, respectively. With an average price target of $21.33 between JP Morgan, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 338.06% upside for ORIC Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Wells Fargo
Jones Trading
Wedbush
1calculated from analyst ratings
Analyst Ratings for ORIC Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/26/2025 | Buy Now | — | Guggenheim | Michael Schmidt51% | — | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 351.75% | JP Morgan | Anupam Rama57% | $21 → $22 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 02/21/2025 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Michael Schmidt51% | — | Maintains | Buy | Get Alert |
| 02/06/2025 | Buy Now | 331.21% | JP Morgan | Anupam Rama57% | $19 → $21 | Maintains | Overweight | Get Alert |
| 01/14/2025 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal34% | — | Reiterates | Overweight → Overweight | Get Alert |
| 01/13/2025 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 11/04/2024 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 310.68% | Wells Fargo | — | → $20 | Initiates | → Overweight | Get Alert |
| 10/31/2024 | Buy Now | 249.08% | Jones Trading | Soumit Roy32% | → $17 | Initiates | → Buy | Get Alert |
| 09/23/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal34% | — | Reiterates | → Overweight | Get Alert |
| 09/18/2024 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 310.68% | Wedbush | David Nierengarten61% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal34% | — | Reiterates | → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 310.68% | Stifel | Bradley Canino40% | → $20 | Initiates | → Buy | Get Alert |
| 08/14/2024 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 310.68% | Wedbush | David Nierengarten61% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 208.01% | Oppenheimer | Matthew Biegler36% | $17 → $15 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | 310.68% | Wedbush | David Nierengarten61% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 07/17/2024 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2024 | Buy Now | 249.08% | Oppenheimer | Matthew Biegler36% | $17 → $17 | Maintains | Outperform | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal34% | — | Reiterates | → Overweight | Get Alert |
| 05/28/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal34% | — | Reiterates | → Overweight | Get Alert |
| 05/07/2024 | Buy Now | 187.47% | Citigroup | Yigal Nochomovitz54% | $15 → $14 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | 269.61% | JP Morgan | Anupam Rama57% | $19 → $18 | Maintains | Overweight | Get Alert |
| 03/21/2024 | Buy Now | 331.21% | HC Wainwright & Co. | Robert Burns41% | $15 → $21 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 310.68% | Wedbush | David Nierengarten61% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 249.08% | Oppenheimer | Matthew Biegler36% | $14 → $17 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 413.35% | Baird | Colleen Kusy34% | $27 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 03/01/2024 | Buy Now | 310.68% | Wedbush | David Nierengarten61% | $12 → $20 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal34% | — | Initiates | → Overweight | Get Alert |
| 12/13/2023 | Buy Now | 208.01% | HC Wainwright & Co. | Robert Burns41% | $16 → $15 | Maintains | Buy | Get Alert |
| 10/26/2023 | Buy Now | 228.54% | HC Wainwright & Co. | Robert Burns41% | $13 → $16 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 187.47% | Wedbush | David Nierengarten61% | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 09/22/2023 | Buy Now | 187.47% | Wedbush | David Nierengarten61% | → $14 | Initiates | → Outperform | Get Alert |
| 08/16/2023 | Buy Now | 454.41% | Baird | Michael Ulz59% | $15 → $27 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 166.94% | HC Wainwright & Co. | Robert Burns41% | $14 → $13 | Maintains | Buy | Get Alert |
| 06/08/2023 | Buy Now | 187.47% | HC Wainwright & Co. | Robert Burns41% | → $14 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 187.47% | HC Wainwright & Co. | Robert Burns41% | $16 → $14 | Maintains | Buy | Get Alert |
| 04/05/2023 | Buy Now | 64.27% | Citigroup | Yigal Nochomovitz54% | $9 → $8 | Maintains | Buy | Get Alert |
| 03/23/2023 | Buy Now | 228.54% | HC Wainwright & Co. | Robert Burns41% | → $16 | Upgrade | Neutral → Buy | Get Alert |
| 03/21/2023 | Buy Now | 208.01% | JP Morgan | Anupam Rama57% | $16 → $15 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 208.01% | Guggenheim | Michael Schmidt51% | → $15 | Downgrade | Buy → Neutral | Get Alert |
| 03/16/2023 | Buy Now | 187.47% | Oppenheimer | Matthew Biegler36% | → $14 | Upgrade | Perform → Outperform | Get Alert |
| 05/20/2022 | Buy Now | 84.8% | Citigroup | Yigal Nochomovitz54% | $10 → $9 | Maintains | Buy | Get Alert |
FAQ
What is the target price for ORIC Pharmaceuticals (ORIC) stock?
The latest price target for ORIC Pharmaceuticals (NASDAQ:ORIC) was reported by Guggenheim on February 26, 2025. The analyst firm set a price target for $0.00 expecting ORIC to fall to within 12 months (a possible -100.00% downside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ORIC Pharmaceuticals (ORIC)?
The latest analyst rating for ORIC Pharmaceuticals (NASDAQ:ORIC) was provided by Guggenheim, and ORIC Pharmaceuticals reiterated their buy rating.
When was the last upgrade for ORIC Pharmaceuticals (ORIC)?
The last upgrade for ORIC Pharmaceuticals Inc happened on March 23, 2023 when HC Wainwright & Co. raised their price target to $16. HC Wainwright & Co. previously had a neutral for ORIC Pharmaceuticals Inc.
When was the last downgrade for ORIC Pharmaceuticals (ORIC)?
The last downgrade for ORIC Pharmaceuticals Inc happened on March 21, 2023 when Guggenheim changed their price target from N/A to $15 for ORIC Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ORIC Pharmaceuticals (ORIC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ORIC Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ORIC Pharmaceuticals was filed on February 26, 2025 so you should expect the next rating to be made available sometime around February 26, 2026.
Is the Analyst Rating ORIC Pharmaceuticals (ORIC) correct?
While ratings are subjective and will change, the latest ORIC Pharmaceuticals (ORIC) rating was a reiterated with a price target of $0.00 to $0.00. The current price ORIC Pharmaceuticals (ORIC) is trading at is $4.87, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
